LETRO-cell® 2

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG, Verastem Inc.

Conditions

Persistent or Recurrent Rare Epithelial Ovarian TumorsRecurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Phase 2

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruitingCTIS2023-508194-89-00

F. Hoffmann-La Roche AGPersistent or Recurrent Rare Epithelial Ovarian Tumors

Start: 2021-08-30Target: 57Updated: 2026-01-06

Phase 3

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP301)

RecruitingCTIS2023-508204-38-00

Verastem Inc.Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Start: 2024-07-02Target: 183Updated: 2026-01-06